Synthesis and antitumor activity of 5-(5′,6′-benzocoumaro-3′-yl)methylaminouracil hydrobromide and its liposomal medicinal form
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The antitumor activity of 5-(5′,6′-benzocoumaro-3′-yl)methylaminouracil (BCMU) and its liposomal medicinal form was studied in comparison to 5-fluorouracil (5-FU), a well-known antitumor drug widely used in oncological practice. The half-lethal dose of BCMU is 14.8 ± 4.2 mg/kg, while the optimum effective dose of the drug is 6 mg/kg. In this dose, BCMU combines low toxicity with significant antitumor activity, which is manifested by increased tumor growth inhibition (TGI) at a 19% increase in the lifetime (LT) of experimental animals. The antitumor activity of the liposomal form of BCMU is quantitatively and qualitatively superior to that of the nonmodified compound and 5-FU, which is manifested by the most pronounced TGI value and by a significant LT increase.
- E. A. Parfenov and L. D Smirnov, Khim.-Farm. Zh., 22(12), 1438–1448 (1988).
- Experimental Evaluation of Antitumor Drugs in USSR and USA [in Russian], Z. P. Sof’ina, A. B. Syrkin, A. Goldin, and K. Kleine (eds.), Meditsina, Moscow (1979).
- I. V. Orlenko, S. N. Kovalenko, I. A Zhuravel’, et al., Fiziol. Aktiv. Rech., No. 3, 25–28 (2001).
- V. G. Budker, T. E. Vakhrusheva, E. V. Keseleva, and N. B. Khristolyubova, Khim.-Farm. Zh., 21(1), 347–352 (1987).
- Synthesis and antitumor activity of 5-(5′,6′-benzocoumaro-3′-yl)methylaminouracil hydrobromide and its liposomal medicinal form
Pharmaceutical Chemistry Journal
Volume 40, Issue 6 , pp 296-297
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Consultants Bureau
- Additional Links
- Industry Sectors